open access

Vol 86, No 5 (2018)
ORIGINAL PAPERS
Published online: 2018-10-30
Submitted: 2018-07-22
Accepted: 2018-09-08
Get Citation

The effectiveness of bronchial artery embolisation in patients with haemoptysis

Daria Magdalena Springer, Szczepan Cofta, Robert Juszkat, Bartosz Żabicki, Joanna Goździk-Spychalska, Agata Nowicka, Hanna Winiarska, Halina Batura-Gabryel
DOI: 10.5603/ARM.2018.0035
·
Pubmed: 30378649
·
Adv Respir Med 2018;86(5):220-226.

open access

Vol 86, No 5 (2018)
ORIGINAL PAPERS
Published online: 2018-10-30
Submitted: 2018-07-22
Accepted: 2018-09-08

Abstract

Introduction: Bronchial artery embolisation (BAE) is one of the methods used in massive and recurring haemoptysis. The aim of
the study is to determine the effectiveness and complications of bronchial artery embolisation in recurring haemoptysis.

Material and methods: The analysis included 47 embolisation procedures performed on 30 patients treated between 2011 and
2017 in the Department of Respiratory Medicine, Allergology and Pulmonary Oncology due to haemoptysis. The patient’s age ranged
between 18 and 71 years, while mean age at the time of BAE was 33.5 years. Patients with tuberculosis constituted 73.33% (n = 22)
of the sample and underwent 31 embolisation procedures in total. The remaining part of the sample (n = 8) collectively underwent 16
BAEs. The analysis was conducted by verifying the medical documentation, as well as carrying face-to-face and phone conversations.

Results: Immediate control due to the inhibition of bleeding was obtained in 95.75% of cases. Recurrence within 3 days of BAE
was reported in 5 patients (10.63%), and 4 re-embolisation procedures were conducted. In 10 patients (33.33%), recurrence
was observed during the first year post-BAE, while it was reported in 17 cases during the whole observation period (56.66% of
patients). The subjects who underwent re-embolisation demonstrated recurrence-free periods lasting from 2 days to 63 months.
In patients with recurrence but no re-embolisation, the shortest and longest haemoptysis-free time was 2 and 35 months, respectively.
11 patients (36.66%) required several embolisation procedures during the whole observation period.

Conclusions: BAE is a highly successful procedure in treating haemoptysis. The risk of complications is low.

Abstract

Introduction: Bronchial artery embolisation (BAE) is one of the methods used in massive and recurring haemoptysis. The aim of
the study is to determine the effectiveness and complications of bronchial artery embolisation in recurring haemoptysis.

Material and methods: The analysis included 47 embolisation procedures performed on 30 patients treated between 2011 and
2017 in the Department of Respiratory Medicine, Allergology and Pulmonary Oncology due to haemoptysis. The patient’s age ranged
between 18 and 71 years, while mean age at the time of BAE was 33.5 years. Patients with tuberculosis constituted 73.33% (n = 22)
of the sample and underwent 31 embolisation procedures in total. The remaining part of the sample (n = 8) collectively underwent 16
BAEs. The analysis was conducted by verifying the medical documentation, as well as carrying face-to-face and phone conversations.

Results: Immediate control due to the inhibition of bleeding was obtained in 95.75% of cases. Recurrence within 3 days of BAE
was reported in 5 patients (10.63%), and 4 re-embolisation procedures were conducted. In 10 patients (33.33%), recurrence
was observed during the first year post-BAE, while it was reported in 17 cases during the whole observation period (56.66% of
patients). The subjects who underwent re-embolisation demonstrated recurrence-free periods lasting from 2 days to 63 months.
In patients with recurrence but no re-embolisation, the shortest and longest haemoptysis-free time was 2 and 35 months, respectively.
11 patients (36.66%) required several embolisation procedures during the whole observation period.

Conclusions: BAE is a highly successful procedure in treating haemoptysis. The risk of complications is low.

Get Citation

Keywords

embolisation, haemoptysis, cystic fibrosis, lung disease

About this article
Title

The effectiveness of bronchial artery embolisation in patients with haemoptysis

Journal

Advances in Respiratory Medicine

Issue

Vol 86, No 5 (2018)

Pages

220-226

Published online

2018-10-30

DOI

10.5603/ARM.2018.0035

Pubmed

30378649

Bibliographic record

Adv Respir Med 2018;86(5):220-226.

Keywords

embolisation
haemoptysis
cystic fibrosis
lung disease

Authors

Daria Magdalena Springer
Szczepan Cofta
Robert Juszkat
Bartosz Żabicki
Joanna Goździk-Spychalska
Agata Nowicka
Hanna Winiarska
Halina Batura-Gabryel

References (18)
  1. Gajewski P, Niżankowska-Mogilnicka E. Interna Szczeklika. Medycyna Praktyczna, Kraków 2017: 609–610.
  2. Sands D. Mukowiscydoza. Choroba wieloukładowa. Termedia Wydawnictwa Medyczne 2018.
  3. Fruchter O, Schneer S, Rusanov V, et al. Bronchial artery embolization for massive hemoptysis: long-term follow-up. Asian Cardiovasc Thorac Ann. 2015; 23(1): 55–60.
  4. Anuradha C, Shyamkumar NK, Vinu M, et al. Outcomes of bronchial artery embolization for life-threatening hemoptysis due to tuberculosis and post-tuberculosis sequelae. Diagn Interv Radiol. 2012; 18(1): 96–101.
  5. Fernando HC, Stein M, Benfield JR, et al. Role of bronchial artery embolization in the management of hemoptysis. Arch Surg. 1998; 133(8): 862–866.
  6. Yoon W, Kim JK, Kim YH, et al. Bronchial and nonbronchial systemic artery embolization for life-threatening hemoptysis: a comprehensive review. Radiographics. 2002; 22(6): 1395–1409.
  7. Bleakley S, Phipps K, Petrovsky B, et al. CKD Prognosis Consortium, Prophylactic Cranial Irradiation (PCI) Collaborative Group, Emerging Risk Factors Collaboration. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy. Radiother Oncol. 2004; 71(2): 163–166.
  8. Jassem E, Jassem J. Pulmonary bleedings. Adv Palliat Med. 2003; 2(1): 23–30.
  9. Brinson GM, Noone PG, Mauro MA, et al. Bronchial artery embolization for the treatment of hemoptysis in patients with cystic fibrosis. Am J Respir Crit Care Med. 1998; 157(6 Pt 1): 1951–1958.
  10. Chalumeau-Lemoine L, Khalil A, Prigent H, et al. Impact of multidetector CT-angiography on the emergency management of severe hemoptysis. Eur J Radiol. 2013; 82(11): e742–e747.
  11. Khalil A, Fedida B, Parrot A, et al. Severe hemoptysis: From diagnosis to embolization. Diagn Interv Imaging. 2015; 96(7-8): 775–788.
  12. Noë GD, Jaffé SM, Molan MP. CT and CT angiography in massive haemoptysis with emphasis on pre-embolization assessment. Clin Radiol. 2011; 66(9): 869–875.
  13. Tepe S. Long term outcomes of bronchial artery embolization for hemoptysis in patients with cystic fibrosis. Gulhane Medical Journal. 2013; 55(1): 27.
  14. Shin BS, Jeon GS, Lee SA, et al. Bronchial artery embolisation for the management of haemoptysis in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2011; 15(8): 1093–1098.
  15. Rashad A, Amin M, El-Azim A, et al. Percutaneous transcatheter vascular embolization for life threatening hemoptysis. Egyptian Journal of Chest Diseases and Tuberculosis. 2013; 62(4): 755–759.
  16. Corr P. Management of severe hemoptysis from pulmonary aspergilloma using endovascular embolization. Cardiovasc Intervent Radiol. 2006; 29(5): 807–810.
  17. Vidal V, Therasse E, Berthiaume Y, et al. Bronchial artery embolization in adults with cystic fibrosis: impact on the clinical course and survival. J Vasc Interv Radiol. 2006; 17(6): 953–958.
  18. Juszkat R, Cofta S, Stanisławska K, et al. Embolizacja tętnicy oskrzelowej w leczeniu nawracającego krwioplucia u pacjentka z mukowiscydozą. Przegl Lek. 2012; 69(7): 347–349.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl